Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Cancer Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 97 results found since Jan 2013.

Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer.
In this study, biocompatible selenium nanoparticles (SeNPs) were loaded with RGDfC peptide to fabricate tumor-targeting gene delivery vehicle RGDfC-SeNPs. Subsequently, RGDfC-SeNPs were loaded with Derlin1-siRNA to fabricate RGDfC-Se@siRNA, which are functionalized selenium nanoparticles. RGDfC-Se@siRNA showed greater uptake in HeLa cervical cancer cells in comparison with that in human umbilical vein endothelial cells (HUVECs), verifying the RGDfC-mediated specific uptake of RGDfC-Se@siRNA. RGDfC-Se@siRNA was capable of entering HeLa cells via clathrin-associated endocytosis, and showed faster siRNA release in a cancer ce...
Source: Drug Delivery - December 14, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy
This study demonstrates that the constructed vesicle in combination with hyperthermia could greatly improve the in vivo stability of siRNA-CPPs and synergistically enhance its cancer therapy efficiency. Graphical abstract
Source: International Journal of Pharmaceutics - April 27, 2016 Category: Drugs & Pharmacology Source Type: research

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells
In conclusion, an efficient liposomal delivery system for the combination of miRNA and siRNA to target the BCSCs was developed and could be used as an efficacious therapeutic modality for breast cancer.Graphical AbstractHerceptin-conjugated cationic liposome can enhance the cellular uptake of let-7 miRNA and CDK4 siRNA toward the HER-2 expressing breast cancer stem cells.
Source: Asian Journal of Pharmaceutical Sciences - May 8, 2019 Category: Drugs & Pharmacology Source Type: research

Liposomal siRNA nanocarriers for cancer therapy.
Abstract Small interfering RNAs (siRNA) have recently emerged as a new class of therapeutics with a great potential to revolutionize the treatment of cancer and other diseases. A specifically designed siRNA binds and induces post-transcriptional silencing of target genes (mRNA). Clinical applications of siRNA-based therapeutics have been limited by their rapid degradation, poor cellular uptake, and rapid renal clearance following systemic administration. A variety of synthetic and natural nanoparticles composed of lipids, polymers, and metals have been developed for siRNA delivery, with different efficacy and safe...
Source: Advanced Drug Delivery Reviews - December 30, 2013 Category: Drugs & Pharmacology Authors: Ozpolat B, Sood AK, Lopez-Berestein G Tags: Adv Drug Deliv Rev Source Type: research

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
Conclusions These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
Source: Pharmaceutical Research - December 17, 2014 Category: Drugs & Pharmacology Source Type: research

Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy
Conclusions Human cancer cells responded to repeat siRNA nanoparticles in a similar fashion after a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
Source: Pharmaceutical Research - November 4, 2015 Category: Drugs & Pharmacology Source Type: research

Inhibition of Cancer Cell Growth by GRP78 siRNA Lipoplex via Activation of Unfolded Protein Response.
Abstract Proteasome inhibitors are a novel class of molecular-targeted anti-cancer drugs that suppress the degradation of malfolded proteins, trigger endoplasmic reticulum (ER) stress, and activate apoptosis signals. Glucose-regulated protein 78 (GRP78), a major ER chaperone, is one of the most important molecules for transduction of unfolded protein response (UPR) signals. In accordance with past findings that expression of GRP78 is elevated in cancer cells and helps to resist stress-induced apoptosis, GRP78 knockdown could be effective in anticancer therapy. We tested this hypothesis and found that transfection ...
Source: Biological and Pharmaceutical Bulletin - April 6, 2014 Category: Drugs & Pharmacology Authors: Matsumura K, Sakai C, Kawakami S, Yamashita F, Hashida M Tags: Biol Pharm Bull Source Type: research

Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration
Publication date: 30 May 2018 Source:International Journal of Pharmaceutics, Volume 543, Issues 1–2 Author(s): Vishakha V. Ambardekar, Rajesh R. Wakaskar, Zhen Ye, Stephen M. Curran, Timothy R. McGuire, Don W. Coulter, Rakesh K. Singh, Joseph A. Vetro RNA interference has tremendous potential for cancer therapy but is limited by the insufficient potency of RNAi molecules after i.v. administration. We previously found that complexation with PLL(30)-PEG(5K) greatly increases the potency of 3′-cholesterol-modified siRNA [Chol-siRNA] in primary murine syngeneic 4T1 breast tumors after i.v. administration but mRNA suppress...
Source: International Journal of Pharmaceutics - March 30, 2018 Category: Drugs & Pharmacology Source Type: research

TARGETED LIPOSOMES FOR siRNA DELIVERY TO CANCER.
CONCLUSION: siRNA delivery mediated by functionalized liposomes is promising, but clinical trials need to be conducted. PMID: 30084323 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Eloy JO, Petrilli R, Raspantini GL, Lee RJ Tags: Curr Pharm Des Source Type: research

Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells
In conclusion, the targeting tLyp-1 exosomes are successfully engineered, and can be used for gene therapy with a high transfection efficiency. Therefore, the engineered targeting tLyp-1 exosomes offer a promising gene delivery platform for future cancer therapy.Graphical AbstractThe tLyp-1-lamp2b plasmid transfected HEK293T cells can secreted tumor targeting tLyp-1 exosomes. By electroporation technology, targeting tLyp-1 exosomes were loaded with siRNA. When targeting tLyp-1 exosome ruptured in cytoplasm, siRNA was loaded into the RNA-induced silencing complex (RISC). The sense (passenger) strand was degraded while the a...
Source: Asian Journal of Pharmaceutical Sciences - May 8, 2019 Category: Drugs & Pharmacology Source Type: research

Nanotechnology-based siRNA Delivery Strategies for Metastatic Colorectal Cancer Therapy
Publication date: Available online 16 July 2019Source: International Journal of PharmaceuticsAuthor(s): Ana Rita Sousa, Ana Vanessa Oliveira, Maria José Oliveira, Bruno SarmentoAbstractColorectal cancer (CRC) is the second most common cause of cancer-related death in the world, mainly due to distant metastases events. The metastatic CRC (mCRC) stages are resistant to the therapeutic recommended. Therefore, it urges the development of more efficient strategies to impair the disease. Small interfering RNA (siRNA) is a well-known silencing tool with impact on targeted cancer therapy, even though in vivo challenges difficult ...
Source: International Journal of Pharmaceutics - July 17, 2019 Category: Drugs & Pharmacology Source Type: research

Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
In this study, novel nanoparticles (PTX/siRNA/FALS) were constructed by using tripeptide lipid (L), sucrose laurate (S), and folate-PEG2000-DSPE (FA) to co-deliver PTX and siRNA. The cancer cell targeting nanoparticle carrier (PTX/siRNA/FALS) showed anticipated PTX encapsulation efficiency, siRNA retardation ability, improved cell uptake and sustained and controlled drug release. It led to significant anti-tumor activity in vitro and in vivo by efficient inhibition of VEGF expression and induction of cancer cell apoptosis. Importantly, the biocompatibility of the carriers and low dosage of PTX required for effective ther...
Source: Drug Delivery - October 26, 2020 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Delivery systems for siRNA drug development in cancer therapy
Publication date: Available online 28 August 2014 Source:Asian Journal of Pharmaceutical Sciences Author(s): Cong-fei Xu , Jun Wang Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten years ago, it has become a promising drug target for the treatment of multiple diseases, including cancer. There have already been some successful applications of siRNA drugs in the treatment of age-related macular degeneration and respiratory syncytial virus infection. However, significant barriers still exist on the road to clinical applications of siRNA drugs, including poor cellular uptake, instabilit...
Source: Asian Journal of Pharmaceutical Sciences - October 12, 2014 Category: Drugs & Pharmacology Source Type: research

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
In this study we aim to develop pegylated siRNA lipoplexes formed using the cationic lipid DOTAP and DSPE-PEG2000, capable to effectively stabilize anti Blimp-1 siRNA and suitable for systemic administration. Two types of pegylated lipoplexes using a classic (C-PEG Lipoplexes) or a post-pegylation method (P-PEG-Lipoplexes) were formulated and compared in their physicochemical properties (size, zeta potential, morphology and structure) and efficiency on PEL cell lines. A stable siRNAs protection was obtained with post pegylation approach (2% molar of DSPE-PEG2000 respect to lipid) resulting in structures with diameters of 3...
Source: European Journal of Pharmaceutics and Biopharmaceutics - November 25, 2015 Category: Drugs & Pharmacology Authors: Belletti D, Tosi G, Forni F, Lagreca I, Barozzi P, Pederzoli F, Vandelli MA, Riva G, Luppi M, Ruozi B Tags: Eur J Pharm Biopharm Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line.
CONCLUSION: Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy. PMID: 28092843 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 12, 2017 Category: Drugs & Pharmacology Authors: Aletaha M, Mansoori B, Mohammadi A, Fazeli M, Baradaran B Tags: Biomed Pharmacother Source Type: research